Apr 18, 2024 | Press Releases
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024...
Apr 15, 2024 | Press Releases
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES, April 15, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”,...
Mar 20, 2024 | Press Releases
LOS ANGELES, CA, March 20, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL...
Mar 5, 2024 | Press Releases
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own wordsLOS ANGELES, CA, March 05, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or...
Feb 21, 2024 | Press Releases
LOS ANGELES, Feb. 21, 2024 — Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder letter. “The past 12 months...
Feb 8, 2024 | Press Releases
LOS ANGELES, CA, Feb. 08, 2024 — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and...
